Rchr
J-GLOBAL ID：202101013562241777
Update date: Apr. 03, 2024
Munakata Tsubasa
ムナカタ ツバサ | Munakata Tsubasa
Affiliation and department：
Job title：
Principal Investigator
Research theme for competitive and other funds (13)：
- 2020 - 2023 Suppression of hepatitis B virus replication by a microRNA inhibitor
- 2017 - 2021 Control of hepatitis B virus genomic replication and maintenance by E2F transfription factors
- 2015 - 2018 iHA-100 exhibited a high efficacy whether administered during the early phase or late phase of H5N1 infection
- 2015 - 2018 脂肪酸合成酵素阻害によるインフルエンザウイルス複製抑制機構の解析
- 2012 - 2016 Tissue macrophages are responsible for inflammatory liver disease in the hepatitis C virus transgenic mice
- 2012 - 2016 Cross-talk regulation of viral replication and fatty acid synthesis by miRNAs
- 2013 - 2015 Influenza viral hemagglutinin-targeted macrocyclic peptides as an antiviral agent
- 2011 - 2012 Influenza viral hemagglutinin-targeted macrocycles as an antiviral agent
- 2010 - 2011 Analysis of the molecular mechanisms for regulation of fatty acid synthesis by a viral infection
- 2009 - 2011 The specific SM molecular species that these endogenous SM species interacted with HCV nonstructural 5B polymerase to enhance viral replication
- 2008 - 2010 The role of sphingolipids in hepatitis C virus replication and its alteration of spingolipids metabolism.
- 2006 - 2010 Replication and pathogenesis of plus strand RNA viruses and double strand RNA viruses
- 2007 - 2008 Analysis of the molecular mechanism for repression of HCV replication by cyclin-dependent kinase inhibitors
Show all
Papers (20)：
-
Hirohito Ishigaki, Fumihiko Yasui, Misako Nakayama, Akinori Endo, Naoki Yamamoto, Kenzaburo Yamaji, Cong Thanh Nguyen, Yoshinori Kitagawa, Takahiro Sanada, Tomoko Honda, et al. An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. Frontiers in Microbiology. 2022. 13. 967019-967019
-
Hirohito Ishigaki, Fumihiko Yasui, Misako Nakayama, Akinori Endo, Naoki Yamamoto, Kenzaburo Yamaji, Cong Thanh Nguyen, Yoshinori Kitagawa, Takahiro Sanada, Tomoko Honda, et al. An attenuated vaccinia vaccine encoding the SARS-CoV-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human ACE2 transgenic mice from SARS-CoV-2 and its variants. 2022
-
Fumihiko Yasui, Yusuke Matsumoto, Naoki Yamamoto, Takahiro Sanada, Tomoko Honda, Tsubasa Munakata, Yasushi Itoh, Michinori Kohara. Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Scientific reports. 2022. 12. 1. 4150-4150
-
Takahiro Sanada, Tomoko Honda, Fumihiko Yasui, Kenzaburo Yamaji, Tsubasa Munakata, Naoki Yamamoto, Makoto Kurano, Yusuke Matsumoto, Risa Kohno, Sakiko Toyama, et al. Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021. Journal of epidemiology. 2021. 32. 2. 105-111
-
Tomoko Honda, Sumiko Gomi, Daisuke Yamane, Fumihiko Yasui, Takuya Yamamoto, Tsubasa Munakata, Yasushi Itoh, Kazumasa Ogasawara, Takahiro Sanada, Kenzaburo Yamaji, et al. Development and Characterization of a Highly Sensitive NanoLuciferase-Based Immunoprecipitation System for the Detection of Anti-Influenza Virus HA Antibodies. mSphere. 2021. 6. 3
ｍore...
MISC (4)：
-
安井文彦, 伊藤靖, 山地賢三郎, 山本直樹, 松本祐介, 真田崇弘, 本田智子, 棟方翼, 石垣宏仁, 仲山美沙子, et al. COVID-19ワクシニアウイルスベクターワクチンの開発. 日本実験動物学会総会講演要旨集(Web). 2022. 69th
-
齊藤誠, 伊藤靖, 安井文彦, 棟方翼, 山根大典, 小沢真, 山地賢三郎, 山本直樹, 本田智子, 真田崇弘, et al. Targeted macrocycles hamper hemagglutinin adsorption and fusion, and have antiviral effects in murine and macaque models of influenza. 日本分子生物学会年会プログラム・要旨集(Web). 2021. 44th
-
安井文彦, 伊藤靖, 石垣宏仁, 仲山美沙子, 山本直樹, 山地賢三郎, CONG Thanh Nguyen, 遠藤彬則, 本田智子, 真田崇弘, et al. 高度弱毒化ワクシニアウイルスDIsを用いたCOVID-19ワクチンの作出と変異株に対する防御効果の検討. 日本ワクチン学会学術集会プログラム・抄録集. 2021. 25th
-
棟方翼, 真田崇弘, 山本直樹, 小原道法. B型肝炎ウイルスの複製を促進するマイクロRNAはプレゲノムRNAを標的とする. 日本ウイルス学会学術集会プログラム・予稿集(Web). 2019. 67th
Patents (3)：
-
B型肝炎ウイルスの複製阻害組成物
-
ANTI-HCV AGENT
-
INHIBITION OF REPLICATION OF HEPATITIS C VIRUS BY CDK INHIBITOR
Education (3)：
- 1998 - 2003 The University of Tokyo Graduate School of Pharmaceutical Sciences
- 1996 - 1998 The University of Tokyo Graduate School of Pharmaceutical Sciences
- 1992 - 1996 The University of Tokyo Faculty of Pharmaceutical Sciences Department of Pharmaceutical Sciences
Professional career (1)：
- Ph.D. (The University of Tokyo)
Work history (4)：
- 2008/11 - 現在 Tokyo Metropolitan Institute of Medical Science
- 2005/08 - 2008/10 The University of Tokyo Graduate School of Medicine, Department of Microbiology
- 2003/09 - 2005/07 The University of Texas Medical Branch at Galveston
- 2003/02 - 2003/08 The University of Tokyo Graduate School of Medicine, Department of Microbiology
Return to Previous Page
